The headline comparison
| Foundayo | Wegovy | |
|---|---|---|
| Generic | Orforglipron | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Form | Daily pill | Weekly injection |
| Mechanism | GLP-1 receptor agonist (small molecule) | GLP-1 receptor agonist (peptide) |
| FDA approved | April 1, 2026 | June 2021 |
| Max weight loss | −11.2% | −14.9% |
| List price/mo | ~$649 | ~$1,350 |
| Cheapest self-pay | $349/mo (LillyDirect 90-day) | $499/mo (Novo savings card) |
| Refrigeration | Not required | Required (unopened) |
| CV outcome data | Not yet | Yes (SELECT trial — 20% MACE reduction) |
Efficacy: Wegovy wins by ~3.7 percentage points
Maximum mean weight loss: Wegovy 14.9% (STEP-1 trial), Foundayo 11.2% (ATTAIN-1). That's a 3.7-point gap — meaningful clinically but smaller than the gap between Wegovy and Zepbound.
Why does Wegovy beat Foundayo? Two factors: (1) injectable semaglutide reaches higher steady-state plasma concentration than oral orforglipron, and (2) semaglutide's peptide structure has slightly broader GLP-1 receptor activity than orforglipron's small molecule.
For most patients, that 3.7-point gap means ~7-9 fewer pounds of total weight loss on Foundayo vs Wegovy over 18 months. Whether that's worth the trade-offs is the personal call.
Convenience: Foundayo wins
Daily pill with no fasting protocol vs. weekly subcutaneous injection. For ~30% of patients (per industry surveys), needle aversion is a meaningful barrier — Foundayo opens access for them.
Travel: Foundayo doesn't need refrigeration. Wegovy unopened pens must stay at 36-46°F (refrigerated). Opened Wegovy pens last 28 days at room temperature, so most travel works — but international trips longer than a month or limited fridge access are a Foundayo win.
Cost: Foundayo is cheaper
Foundayo list price ~$649/mo, LillyDirect cash-pay $149-349/mo. Wegovy list ~$1,350/mo, Novo savings card $499/mo for commercially-insured. With insurance approval both cost $25-100/mo copay.
For uninsured or under-insured patients, Foundayo via LillyDirect 90-day at $349/mo is the cheapest legitimate FDA-approved GLP-1 option. See our full Foundayo cost breakdown.
Side effects: similar profile, slight differences
Both have the GLP-1 class side-effect profile: nausea, diarrhea, constipation. Wegovy has higher individual symptom rates but lower overall discontinuation; Foundayo has lower individual rates but higher discontinuation in dose-escalation weeks.
See our Foundayo side-effect deep dive for the complete picture.
Who should pick which
Pick Foundayo if:
- • You refuse injections / have needle aversion
- • Self-pay budget under $500/mo
- • Frequent traveler, fridge logistics matter
- • Already on Rybelsus and want the no-fasting variant
- • Goal: 10-15% weight loss (not maximum)
Pick Wegovy if:
- • Insurance covers Wegovy preferentially
- • Established cardiovascular disease (SELECT data)
- • Want the most-established drug
- • Goal: 15%+ weight loss
- • Comfortable with weekly injection
Find providers carrying both
Some telehealth providers carry only injectables; others have full formulary including Foundayo. Compare your options.
See top providers →Frequently asked questions
- Which works better, Foundayo or Wegovy?
- Wegovy by absolute weight loss: ~14.9% vs Foundayo ~11.2% at maximum doses. But Foundayo is a pill with no fasting protocol, vs Wegovy weekly injection. The "better" depends on which trade-off you value more.
- Is Foundayo cheaper than Wegovy?
- Yes. Foundayo list price ~$649/mo vs Wegovy ~$1,350/mo. LillyDirect cash-pay Foundayo $149-349/mo. Insurance and Medicare Bridge coverage of both is similar.
- Can I switch from Wegovy to Foundayo?
- Yes. Same drug class (GLP-1 agonist), no washout needed beyond standard 7 days. Discuss with your prescriber — they may match dose intensity (e.g. Wegovy 1.7-2.4 mg ≈ Foundayo 24-36 mg).
- Why would I pick Foundayo over Wegovy?
- Three main reasons: no needles (oral pill), lower cash-pay cost, no refrigeration logistics (good for travel). For patients who refused injectable GLP-1s previously, Foundayo opens access.
- Why would I pick Wegovy over Foundayo?
- Higher absolute weight loss (~15% vs ~11%), well-established safety profile (5+ years post-launch), insurance plans more likely to cover, cardiovascular outcome data (SELECT trial).
Disclosure: Affiliate-funded but editorially independent. Trial data from primary literature.